HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide

Figure 1

Different platforms of GvHD prophylaxis for patients undergoing a haploidentical stem cell transplant. ATG: programs based on antithymocyte globulin (ATG) include the original Chinese protocol [5] using bone marrow (BM) + G-mobilized peripheral blood (G-PG) and cyclosporin (CsA), mycophenolate (MMF), and methotrexate (MTX). Also it includes the modified G-mobilized BM (G-BM) + CsA + MMF + MTX + basiliximab [18]. PT-CY: programs based on posttransplant cyclophosphamide (PT-CY). The original Baltimore protocol [6], with unmanipulated BM, a calcineurin inhibitor (CNI), and MMF. The modified program with rapamycin and G-PB [12] and the double step approach [14] ATG + PT-CY. The combined use of ATG + PT-CY as proposed by the Baltimore group in sickle cell disease [19], or by the French cooperative group using G-PB as a stem cell source (unpublished).